NCT02402933View on ClinicalTrials.gov

Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
HypoglycemiaDiabetes Mellitus
Interventions
DRUG

Nasal Glucagon

3 mg nasal glucagon powder

Trial Locations (3)

21229

Private Clinic, Baltimore

32308

Private Clinic, Tallahassee

02451-1136

New England Diabetes and Endocrinology Center (NEDEC), Waltham

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02402933 - Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents | Biotech Hunter | Biotech Hunter